Table III.
Relationship between the expression of miRNA-145 and the clinicopathological characteristics of the study group.
| Category | N | Study group (n=132) | t | P-value |
|---|---|---|---|---|
| Age (years) | 1.780 | 0.077 | ||
| <60 | 48 | 1.79±0.41 | ||
| ≥60 | 84 | 1.92±0.40 | ||
| Sex | 1.161 | 0.248 | ||
| Male | 85 | 1.81±0.43 | ||
| Female | 47 | 1.90±0.42 | ||
| Body mass index (kg/m2) | 1.489 | 0.139 | ||
| <24 | 76 | 1.82±0.44 | ||
| ≥24 | 56 | 1.93±0.39 | ||
| Degree of differentiation | 13.200 | <0.01 | ||
| Middle, low | 75 | 1.62±0.24 | ||
| High | 57 | 2.13±0.19 | ||
| Lymph node metastasis | 8.227 | <0.01 | ||
| Yes | 74 | 1.67±0.29 | ||
| No | 58 | 2.07±0.25 | ||
| Tumor diameter (cm) | 10.460 | <0.01 | ||
| <5 | 48 | 2.11±0.21 | ||
| ≥5 | 84 | 1.66±0.28 | ||
| TNM staging | 8.972 | <0.01 | ||
| I–II | 54 | 2.08±0.24 | ||
| III–IV | 78 | 1.66±0.28 |